Collegium Pharma (COLL) Misses Q4 EPS by $1.77

Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.73), $1.77 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $27.36 million versus the consensus estimate of $81.61 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• JPMorgan Starts Zensho Holdings (7550:JP) at Overweight
• JPMorgan Reinstates Dauch Corporation (DCH) at Neutral